| Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model B Yadav, K Wennerberg, T Aittokallio, J Tang Computational and Structural Biotechnology Journal 13, 504-513, 2015 | 743 | 2015 |
| Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaISM Approach to Therapy Selection T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013 | 480 | 2013 |
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 368 | 2014 |
| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 161 | 2020 |
| PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells O Kauko, CM O’Connor, E Kulesskiy, J Sangodkar, A Aakula, S Izadmehr, ... Science translational medicine 10 (450), eaaq1093, 2018 | 155 | 2018 |
| Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ... Nature Communications 9 (1), 1567, 2018 | 140 | 2018 |
| Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid LeukemiaAML Functional Molecular Precision Medicine D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer Discovery 12 (2), 388-401, 2022 | 134 | 2022 |
| JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ... Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017 | 133 | 2017 |
| Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL A Schrader, G Crispatzu, S Oberbeck, P Mayer, S Pützer, J von Jan, ... Nature communications 9 (1), 1-22, 2018 | 109 | 2018 |
| Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection OV Denisova, L Kakkola, L Feng, J Stenman, A Nagaraj, J Lampe, ... Journal of Biological Chemistry 287 (42), 35324-35332, 2012 | 106 | 2012 |
| Breeze: an integrated quality control and data analysis application for high-throughput drug screening S Potdar, A Ianevski, JP Mpindi, D Bychkov, C Fiere, P Ianevski, B Yadav, ... Bioinformatics 36 (11), 3602-3604, 2020 | 103 | 2020 |
| Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways J Tang, L Karhinen, T Xu, A Szwajda, B Yadav, K Wennerberg, ... PLoS computational biology 9 (9), e1003226, 2013 | 103 | 2013 |
| Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer K Saeed, V Rahkama, S Eldfors, D Bychkov, JP Mpindi, B Yadav, ... European urology 71 (3), 319-327, 2017 | 100 | 2017 |
| Consistency in drug response profiling JP Mpindi, B Yadav, P Östling, P Gautam, D Malani, A Murumägi, ... Nature 540 (7631), E5-E6, 2016 | 100 | 2016 |
| HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017 | 98 | 2017 |
| Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ... Leukemia, 2017 | 96 | 2017 |
| Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells P Gautam, L Karhinen, A Szwajda, SK Jha, B Yadav, T Aittokallio, ... Molecular cancer 15 (1), 1-16, 2016 | 76 | 2016 |
| Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1 O Kauko, SY Imanishi, E Kulesskiy, L Yetukuri, TD Laajala, M Sharma, ... Journal of Biological Chemistry 295 (13), 4194-4211, 2020 | 63 | 2020 |
| Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ... Leukemia 33 (6), 1360-1372, 2019 | 61 | 2019 |
| Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017 | 59 | 2017 |
Tero AittokallioUniversity of Helsinki, University of Turku, University of OsloVerified email at utu.fi
